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Abstract Hereditary diffuse gastric cancer (HDGC) has
been shown to be caused by germline mutations in the gene
CDH1 located at 16q22.1, which encodes the cell–cell
adhesion molecule, E-cadherin. Not only does loss of
expression of E-cadherin account for the morphologic
differences between intestinal and diffuse gastric cancer
(DGC) variants, but it also appears to lead to distinct cel-
lular features which appear to be common amongst related
cancers that have been seen in the syndrome. As in most
hereditary cancer syndromes, multiple organ sites may be
commonly affected by cancer, in HDGC, lobular carci-
noma of the breast (LBC) and possibly other organ sites
have been shown to be associated with the familial cancer
syndrome. Given the complexity of HDGC, not only with
regard to the management of the DGC risk, but also with
regard to the risk for other related cancers, such as LBC, a
multi-disciplinary approach is needed for the management
of individuals with known CDH1 mutations.
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Introduction
Despite an overall decrease in the global incidence of
gastric cancer (GC) [1], the incidence of the subtype,
diffuse gastric cancer (DGC) has remained stable and may
even be increasing [2]. Within the past ten years, germline
mutations in CDH1, which encodes E-cadherin, have been
found [3] in over 50% of hereditary diffuse gastric cancer
(HDGC) families with at least two cases of GC, with one
diagnosed as DGC before the age of 50 years [4]. Within
these HDGC families, we and others have noted an over-
representation of lobular breast cancer (LBC) [4–8]. This
observation has led to efforts to determine whether or not
CDH1 is a breast cancer susceptibility gene, distinct from
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novel germline CDH1 truncating mutation (517insA) in an
LBC family with no known history of GC [9]. Within this
review we report a germline CDH1 mutation in a second
family in which breast cancer is the predominant cancer
diagnosis. The management of HDGC in all patients with a
particular focus on the management of the breast cancer
risk associated with germline CDH1 mutations will be
discussed.
Methods
The described family was referred to the ongoing HDGC
study at the British Columbia Cancer Agency from a
cancer genetics clinic in Seattle, WA, USA. Informed
consent was obtained from the proband by the referring
genetic counselor following ascertainment of a detailed
cancer family history and appropriate genetic counseling
prior to germline mutation testing. Our laboratory carried
out the molecular genetic testing for the CDH1 mutation on
a research basis. Approval for the HDGC study is by the
clinical research ethics board of the University of British
Columbia.
Theproband(IV-4)wasdiagnosedwithwidelymetastatic
lobularbreastcanceratage53 years(Fig. 1a).Herfamily,of
European ancestry, had a history of breast cancer diagnoses
occurring in an autosomal dominant fashion on the maternal
side of the family where her mother, aunt, and ﬁrst cousin
developed breast cancer in their 50’s. Due to her high-risk
pedigree BRCA1, BRCA2, and PTEN genetic testing was
undertaken and all were negative. CDH1 testing was also
pursued.
Results
All 16 exons were ampliﬁed for DHPLC analysis [6]. For
exon 10 of CDH1, the initial amplicon failed and was
therefore analyzed by direct sequencing and thus revealed a
donor splice site mutation, 1565 + 1G[A (Fig. 1b). Due
to its position at a donor splice site, this mutation is
regarded as pathogenic [10].
The proband’s sisters (IV-2 and IV-6) participated in all
aspects of the proband’s genetic consultation. They were
appropriately concerned about their risk of breast cancer,
but had not thought much about the possibility of getting
gastric cancer until the CDH1 mutation was found. IV-2
and IV-6 had predictive genetic testing for the CDH1
mutation testing and both were found to be negative. Other
family members are being informed about the availability
of predictive genetic testing.
Fig. 1 (a) Pedigree of family
reported showing a
predominance of breast cancer.
(b) Sequence from family
carrying 1565 + 1G?A
mutation
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E-cadherin
CDH1 (OMIM *192090), located on chromosome 16q22.1
encodes, E-cadherin, an epithelial transmembrane cell–cell
adhesion molecule and member of the cadherin superfamily
of glycoproteins. In a zipper-like fashion, its extracellular
domain forms calcium-dependent homodimers between the
E-cadherin molecules of adjacent epithelial cells, to act as
the primary mediator of epithelial cell adhesion at the
adherens junction complex [11]. Through interactions of its
cytoplasmic tail with multiple signalling and structural
molecules, such as the catenins, E-cadherin, maintains cel-
lularadhesionandepithelialarchitecturewiththislinktothe
cytoskeleton. The cytoplasmic tail of E-cadherin directly
associates with b-catenin and c-catenin which in turn binds
to the f-actin microﬁlaments of the cytoskeleton, directly or
through a-catenin [12]. p120-catenin also associates with
E-cadherin’s cytoplasmic tail at a different site, the juxta-
membrane domain, and acts to both strengthen the adhesion
between cells and regulate cadherin membrane trafﬁcking
anddegradation[13,14].E-cadherinisconsideredtohavean
invasion suppressor role, where decreased expression per-
mits cells to dissociate from each other in order to migrate
and invade [15]. In cancers, this manifests as increased
inﬁltrative and metastatic potential [16]. E-cadherin is also
thoughttoact asa tumour suppressor, potentiallythrough its
interactionwiththemultipurposeb-cateninmoleculewhich
is an effector of the WNT signalling pathway [17]. Loss of
E-cadherin can result in b-catenin release from the mem-
brane and translocation to the nucleus where it complexes
with Tcf/Lef-1 transcription factors to initiate transcription
of WNT responsive genes [18]. Activation of these genes
have been implicated in tumourigenesis through the WNT
signalling pathway as seen in adenomatous polyposis coli
(APC) [19]. In support of the role of E-cadherin as a tumour
suppressor is the observation of abnormal or absent E-cad-
herin expression in precursor lesions of DGC and LBC,
where the phenomenon is seen in in situ signet ring cell
carcinomas found in prophylactic gastrectomy specimens
from germline CDH1 mutation carriers [20] and the lobular
carcinoma in situ lesions seen adjacent to invasive lobular
breast cancers [21]. These examples suggest that loss of
E-cadherin is an early or even tumour-initiating event,
howevertheactualmolecularbasisofsuchapotentialroleof
E-cadherin in such cases is unknown.
Inactivating CDH1 mutations are found in 50% of
sporadic DGCs [22, 23] and cluster between exons seven
and nine [11], in contrast with the low percentage of
mutations seen in sporadic intestinal type GCs [23].
Decreased expression of E-cadherin in DGCs may account
for morphologic differences between intestinal and DGC
variants [24]. Unlike somatic CDH1 mutations, germline
mutations associated with DGC are distributed throughout
the gene [7] (Fig. 2). In the cancers from individuals with
CDH1 mutations, CDH1 acts as a classic tumour sup-
pressor gene with loss of expression of the wildtype allele
[25, 26]. In a single study of 6 hereditary DGC cancers,
inactivation of the wild-type allele could be attributed to
promoter hypermethylation in 5 (83%) of cases [26]. This
ﬁnding warrants veriﬁcation in a larger cohort as abnormal
promoter methylation in early cancers could potentially
form the basis of a screening test.
Fig. 2 DGC and LBC associated CDH1 germline mutations. Muta-
tions shown above CDH1 gene schematic occur in families with DGC
history and those below CDH1 occur in families with an additional or
exclusive LBC history. In addition to the known CDH1 germline
mutations compiled by Kaurah et al. [4], the recent mutation in an
LBC family [9] and novel mutation from this paper are shown and
identiﬁed below the symbol denoting mutation type. * Denotes the
halfway point of the CDH1 coding sequence (1324 or the start of exon
10)
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Currently germline mutations in single genes account for
approximately 5–10% of breast cancer [27]. High pene-
trance genes such as BRCA1 and 2 account for 3–8%, and
TP53 and PTEN as seen in Li-Fraumeni and Cowden
syndrome together only account for\0.1% of breast cancer
diagnoses [28]. Other medium and low penetrance genes
such as CHK2, BRIP1, PALB2 and ATM [29–32] have been
identiﬁed, however, there still remains a proportion of
hereditary breast cancer not yet determined. LBC accounts
for approximately 10% of all breast cancers compared to
the other major histologic subtype, invasive ductal carci-
noma (IDC) [33]. Several factors suggest that LBC has a
stronger hereditary basis relative to IDC, such as the higher
frequency of bilateral disease [33], and also where excess
familiality of LBC has been observed in population studies
[34]. LBCs compose only 3% and 9% of the breast cancer
tumour types seen in germline BRCA 1 and 2 mutation
carriers, respectively [35], illustrating that the genetic risk
factors for the majority of cases are unaccounted for by
these genes.
The histology of LBC is characterized by inﬁltrative
cancer cells which are isolated, highly dispersive and
demonstrate a growth pattern with scattered and single ﬁles
of tumor cells dispersed in stromal tissue [36]. This path-
ologic appearance is remarkably similar to DGCs and both
LBC and DGC demonstrate characteristic mucinous, signet
ring cells. This is not unexpected as E-cadherin staining is
absent in 85% of sporadic invasive LBC [37] and somatic
CDH1 mutations have been identiﬁed in 56% of sporadic
LBCs [38]. Furthermore, in IDC, somatic CDH1 mutations
are not found [38] and complete loss of E-cadherin
expression is an uncommon feature. As loss of E-cadherin
expression is a distinctive trait of both LBCs and DGCs, it
likely contributes to the unique histopathologic features
shared by the two cancers.
There are some differences with regard to the nature of
the mutations seen in LBC and DGC. Generally mutations
associated with sporadic LBC have been found to be
nonsense or frameshift mutations [39] which encode
truncated, non-functional proteins, whereas in sporadic
DGC, mutations have generally been found to be splice
site and in-frame mutations [11]. In sporadic LBC,
mutations in CDH1 are spread throughout the gene [11]
compared with the mutations seen in sporadic DGC which
tend to cluster. Germline CDH1 mutations associated with
DGC and/or LBC occur throughout the gene (Fig. 2).
However, when the DGC and LBC associated CDH1
mutations are tabulated and compared based on their 30 or
50 positions relative to the halfway point of the CDH1
coding sequence (1324 or the start of exon 10), LBC
associated mutations show a statistically signiﬁcant trend
towards clustering at the 30 end (Fisher’s exact test, two-
tailed P-value equals 0.0467) (Fig. 2). As this association
is of weak statistical signiﬁcance, it is unlikely to impact
clinical testing strategies. Future analyses of novel
germline LBC-associated CDH1 mutations should help to
conﬁrm this observation. Another difference between the
molecular genetics of the two types of cancers, is that in
sporadic LBC, silencing of E-cadherin expression is
generally accomplished by a mutation in one allele in
combination with loss of heterozygosity (LOH) or pro-
moter hypermethylation in the remaining allele [40]. This
is in contrast to sporadic DGC, where biallellic inactiva-
tion is achieved by mutations in one allele in concert with
promoter hypermethylation in the other [41].
We have recently identiﬁed a truncating germline CDH1
mutation in an LBC family where analysis of the tumour
was suggestive of partial LOH in the WT allele [9]. Our
current case demonstrates a germline CDH1 mutation
(1565 + 1G[A) in a predominantly breast cancer family,
which is predicted to disrupt splicing. The mutation is in
the same conserved position as a previously reported
mutation (1565 + 1G[T) which was found in an Arabian
HDGC family with no recorded history of breast cancer
[42]. Moreover, a previous study reported a germline
missense mutation in a proband with LBC but did not detail
family history, or functionally characterize the missense
mutation [43]. These examples demonstrate the need for
further studies of germline mutations in LBC families in
order to determine the mutation frequency and potential
genotype-phenotype correlations.
Lobular breast cancer and HDGC
Breast cancer has been observed in HDGC kindreds to the
extent where clustering of LBCs within HDGC families has
led to the misclassiﬁcation of families as breast cancer
kindreds who test negative for BRCA1/2 mutations [4]. In
1998, Keller described the ﬁrst case of histologically
deﬁned LBC in association with HDGC [5]. Since then,
several more HDGC families with associated breast cancer
were reported where it was observed, that these cases were
LBCs when pathology was available [4, 6–8].
Prior to establishment of the association between HDGC
and LBC, several efforts to determine whether CDH1 was a
breast cancer susceptibility gene were attempted in view of
the well-recognised phenotype of loss of E-cadherin
expression displayed by the breast cancer subtype. For
various reasons these studies failed to demonstrate the link.
Rahman et al. examined 65 cases of lobular carcinoma
in situ, however did not pre-screen the cases based on
family history and included a wide age range, from 26 to
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12371 years, not necessarily in keeping with the usual age of
onset seen in hereditary cancer syndromes [44]. Salashor
examined 19 breast cancer tumours exhibiting LOH at the
CDH1 locus, however of those, only 3 were conﬁrmed to
be pure LBC or mixed LBC/IDC pathology [45]. Lei
examined 13 familial LBC cases and found no mutations,
however did not deﬁne the extent of the family history
[46].
Penetrance data based on 11 HDGC families, estimated
the cumulative risk for LBC for female mutation carriers to
be 39% (95% CI, 12–84%) by 80 years of age [47]. More
recently we have published an estimated cumulative risk
for breast cancer for females by the age of 75 years as
being 52% (95% CI, 29–94%) from analysis of 4 pre-
dominantly gastric cancer pedigrees from Newfoundland
with the 2398delC CDH1 founder mutation [4]. This is
with the caveat that LBC risk for CDH1 mutation carriers
has been assessed within high risk HDGC families, leading
to a potential ascertainment bias and underestimation of the
role of CDH1 mutations in LBC development. To
accommodate for this we have begun analysis of CDH1
mutations within familial lobular breast cancer families or
those families ascertained through a relatively young index
case with conﬁrmed LBC and have found germline CDH1
mutations in these kindreds [9].
Clinical implications of CDH1 associated LBC risk
At this time, it seems reasonable to conclude that at least
four groups of women are at increased risk for LBC:
women with LBC and a family history of breast cancer,
women with a known CDH1 mutation, women from fam-
ilies with diffuse gastric cancer in whom no CDH1
mutation has yet been identiﬁed; and women with a
germline BRCA2 mutation. Since there has not yet been a
large population based study of the prevalence of CDH1
mutations among women with lobular breast cancer, it is
premature to recommend genetic evaluation to women with
a family history of breast cancer unless, at the very least,
one of the breast cancers can be shown to have been lob-
ular. Additional research can be expected to provide better
guidance for these families.
Although there are not yet deﬁnitive data available on
surveillance or risk reduction programs for women with
known CDH1 mutations or untested women from CDH1-
positive families, the high lifetime risk of LBC (39–52%)
[4, 47] that these women face mandates their careful
management. We suggest that they follow the recommen-
dations for other high-risk women with hereditary breast
cancer predisposition. This subgroup should be advised to
practice breast self-examination; and to have annual
mammograms, and semiannual clinical breast examination,
beginning at least by age 30. There is certainly interest in
regular bilateral breast MRI, as lobular breast cancer are
known to frequently elude mammographic detection
because they do not form masses or develop calciﬁcations.
These women can also be counseled to consider hormonal
chemoprevention, since most LBCs are estrogen receptor
positive [33], and both tamoxifen and raloxifene reduce the
risk of estrogen receptor positive [48, 49] breast cancers in
randomized trials. In addition, the risk reduction was
greatest with both agents in women with lobular carcinoma
in situ [50].
Prophylactic mastectomy may also be considered an
option by some CDH1-positive women, particularly those
who have been previously diagnosed with breast cancer in
one breast or those who have had to undergo multiple
biopsies for abnormal clinical ﬁndings. Several studies
have reported a 90% reduction in breast cancer incidence
with prophylactic mastectomy among women with a strong
family history or with a germline BRCA1 or BRCA2
mutation [51, 52]. The published series include some lob-
ular breast cancers, but not at numbers sufﬁcient to permit
meaningful subset analysis at this time.
Management of hereditary diffuse gastric cancer
Penetrance studies examining data from HDGC families,
have estimated the lifetime risk of developing gastric
cancer by age 75 and 80 respectively, to be from 40–67%
in men, to 63–83% in women [4, 47]. Although identiﬁ-
cation of germline CDH1 mutations has enabled a
signiﬁcant proportion of HDGC families to utilise predic-
tive testing to determine their individual risks of GC within
CDH1 mutation positive pedigrees, unfortunately screen-
ing for DGC is ineffective and the current recommendation
is for consideration of prophylactic gastrectomy in muta-
tion positive individuals. Positron emission tomography
[53] and chromoendoscopic-directed biopsies [54] have
been proposed over basic endoscopy as more sensitive
means of screening carriers, however screening methods
have been consistently undermined by the recurrent dis-
covery of multifocal DGC lesions underlying normal
mucosa in prophylactic gastrectomy specimens of indi-
viduals with recent negative screening [4, 55, 56].
Regardless of the current limitations of screening, it is
currently recommended that consideration for genetic
testing and screening begin in at risk individuals in the late
teens or early twenties [4] and that prophylactic total gas-
trectomy be considered in the early twenties for mutation
carriers. Female mutation carriers will need specialized
counseling to the potential nutritional effects on pregnancy
following gastrectomy [57]. Further studies are currently
underway to examine the quality of life impact of
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123prophylactic gastrectomies. In the case report herein,
although there was a GC in the maternal grandfather, the
family history was more striking for the large number of
breast cancer cases. This highlights the particular chal-
lenges we currently face with regard to counseling these
families which appear to be mainly breast cancer, as it is
unknown if the penetrance of DGC in this family is as high
as it is in other HDGC pedigrees.
Conclusion
HDGC is one of a number of hereditary cancer syndromes
that feature both an increased breast and gastric cancer risk
(Table 1). In general, a lack of shared genetic risks for
most breast and GI cancers was suggested through a recent
study of 13,023 genes in 11 breast and 11 colon cancer cell
lines in which the only commonly mutated gene between
these two cancer types is p53 [58]. This likely reﬂects
underlying differences in the biology of these diseases,
however also highlights the unique nature of germline
mutations in the CDH1 gene which are strongly associated
with speciﬁc histologically deﬁned subtypes of breast and
GI cancer, namely LBC and DGC which are both part of
the HDGC syndrome.
With the recent demonstration of a CDH1 mutation in a
family ascertained through an index case of LBC and in
view of the additional new mutation in a predominantly
breast cancer family that we have described here, the
evidence for establishing LBC as part of the HDGC syn-
drome is strong. There now is a need for establishing the
prevalence of CDH1 mutations in LBC families to avoid
the ascertainment bias generated from only looking at
cases from families identiﬁed because of their family his-
tory of GC. It is not currently known what the risk of GC is
in these families which present predominantly as having a
susceptibility to breast cancer and therefore identiﬁcation
of CDH1 as a true susceptibility gene for LBC could result
in CDH1 screening and effective risk reduction strategies
for selected breast cancer families and further studies
examining their risk for gastric and other cancers.
Most hereditary cancer syndromes are associated with
cancer risk involving multiple organs. Here we have dis-
cussed germline CDH1 mutations and the risks with regard
to DGC and LBC, however as the recognised spectrum of
related cancers broadens, more affected families will be
identiﬁed and successfully managed with regard to
avoidance of speciﬁc cancer risks. Longer life expectancy
in individuals with penetrant mutations could potentially
lead to the development of different, later onset disease as
yet to be identiﬁed in these kindreds. This represents a
particular challenge in hereditary cancer practice as the
clinical community tends to be segregated into organ
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123speciﬁc specialties where as the cancer risks and the risk
reduction strategies for germline mutation carriers require
a variety of expertise. The medical needs of the HDGC
families are therefore best served through an engaged
multidisciplinary team.
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